December 1, 2015
Routine use of radiation therapy appeared to prolong failure-free survival among patients with nonmetastatic, newly diagnosed prostate cancer regardless of nodal status, according to findings from the control arm of the STAMPEDE trial.
The STAMPEDE trial is a multiarm, multistage study of men with prostate cancer starting first-line hormone therapy. Researchers are evaluating the impact of the addition of treatments to hormone-based therapy. The control arm of the study evaluates the use of hormone therapy with radiotherapy when appropriate — radiation was offered to nonmetastatic patients at the start of the trial, but it became mandatory in November 2011 based on data from other reports.